Suppr超能文献

影响伴有残留肿瘤的生长激素分泌型垂体神经内分泌肿瘤激素缓解的因素:一项回顾性队列研究

Factors Influencing Hormone Remission in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors With Residual Tumor: A Retrospective Cohort Study.

作者信息

Wang Yangyang, Ma Li, Zhang Chuanbao, Ma Shunchang, Jia Guijun, Jia Wang, Guan Xiudong

机构信息

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

出版信息

CNS Neurosci Ther. 2025 Aug;31(8):e70574. doi: 10.1111/cns.70574.

Abstract

BACKGROUND

Growth hormone-secreting pituitary neuroendocrine tumors (GH-secreting PitNETs) pose significant health risks due to hormone-related complications. Despite transsphenoidal surgical resection being the primary treatment, complete removal is often infeasible due to invasive growth patterns, leading to postoperative tumor residuals and uncertain hormone remission outcomes.

METHODS

This retrospective study included 458 patients with GH-secreting PitNETs who underwent surgery at Beijing Tiantan Hospital. Data on preoperative hormone levels, MRI scans, and histopathological features were analyzed. Tumor segmentation, intratumor heterogeneity (ITH) scores, and subcluster clustering based on MRI data were computed using radiomic features, while multivariate analyses determined factors influencing hormone remission. Single-cell data from four GH-type pituitary adenomas were collected from public databases to explore ITH in GH1 gene expression.

RESULTS

Postoperative hormone remission was achieved in 61 of 144 patients (42.4%) with residual tumors. Univariate analysis demonstrated that in cases with tumor residuals, preoperative hormone levels, tumor resection rates, residual tumor volume, tumor residual location, residual-tumor proximity to the internal carotid artery, and MRI-based tumor heterogeneity were associated with hormone remission. Among these factors, preoperative hormone levels (10-30 ng/mL vs. ≤ 10 ng/mL: OR: 0.48, 95% CI 0.20-1.19, p = 0.115; > 30 ng/mL vs. ≤ 10 ng/mL: OR: 0.13, 95% CI: 0.04-0.36, p < 0.001), tumor resection rate (OR: 18.29, 95% CI: 2.08-160.97, p = 0.009), and tumor heterogeneity as measured by the ITH score (OR: 1.06, 95% CI: 1.00-1.12, p = 0.042) were independent predictors of hormone remission in cases with residual tumors. Moreover, single-cell data showing highly variable GH1 expression within the same patient reveal ITH in hormone expression.

CONCLUSION

Preoperative GH levels, tumor resection rates, and ITH scores independently predict hormone remission in GH-secreting PitNETs with residuals. This will provide intraoperative decision-making guidance on how to achieve the maximum possible hormone remission with residual tumors when complete tumor resection is not feasible.

摘要

背景

分泌生长激素的垂体神经内分泌肿瘤(GH分泌型垂体神经内分泌肿瘤)因激素相关并发症而带来重大健康风险。尽管经蝶窦手术切除是主要治疗方法,但由于侵袭性生长模式,完全切除往往不可行,导致术后肿瘤残留以及激素缓解结果不确定。

方法

这项回顾性研究纳入了458例在北京天坛医院接受手术的GH分泌型垂体神经内分泌肿瘤患者。分析了术前激素水平、MRI扫描和组织病理学特征的数据。使用放射组学特征计算基于MRI数据的肿瘤分割、瘤内异质性(ITH)评分和亚簇聚类,同时多变量分析确定影响激素缓解的因素。从公共数据库收集了来自4例GH型垂体腺瘤的单细胞数据,以探索GH1基因表达中的ITH。

结果

144例有肿瘤残留的患者中,61例(42.4%)术后实现了激素缓解。单变量分析表明,在有肿瘤残留的病例中,术前激素水平、肿瘤切除率、残留肿瘤体积、残留肿瘤位置、残留肿瘤与颈内动脉的距离以及基于MRI的肿瘤异质性与激素缓解相关。在这些因素中,术前激素水平(10 - 30 ng/mL与≤10 ng/mL相比:OR:0.48,95%CI 0.20 - 1.19,p = 0.115;>30 ng/mL与≤10 ng/mL相比:OR:0.13,95%CI:0.04 - 0.36,p < 0.001)、肿瘤切除率(OR:18.29,95%CI:2.08 - 160.97,p = 0.009)以及通过ITH评分测量的肿瘤异质性(OR:1.06,95%CI:1.00 - 1.12,p = 0.042)是有肿瘤残留病例中激素缓解的独立预测因素。此外,同一患者内显示GH1表达高度可变的单细胞数据揭示了激素表达中的ITH。

结论

术前GH水平、肿瘤切除率和ITH评分可独立预测有残留的GH分泌型垂体神经内分泌肿瘤的激素缓解情况。这将为在无法实现肿瘤完全切除时如何使残留肿瘤实现最大可能的激素缓解提供术中决策指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b27b/12376067/614214dbbfea/CNS-31-e70574-g004.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验